Praxis Precision Medicines, Inc. $PRAX Shares Sold by B Group Inc.

Core Insights - B Group Inc. reduced its holdings in Praxis Precision Medicines by 10.0% during Q3, now owning 31,500 shares, which is approximately 1.3% of its portfolio, valued at $1,670,000 [2] - Several large investors have adjusted their positions in Praxis Precision Medicines, with notable increases from MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. (5.1% increase), UBS AM (367.8% increase), and Geode Capital Management (8.1% increase) [3] - Praxis Precision Medicines has a market cap of $8.19 billion, with a PE ratio of -21.84 and a beta of 2.86, indicating high volatility [4] Investor Activity - MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,708 shares valued at $444,000 after a 5.1% increase [3] - UBS AM increased its stake significantly by 367.8%, now holding 87,081 shares worth $3,298,000 [3] - Geode Capital Management owns 451,731 shares valued at $18,997,000 after an 8.1% increase [3] Stock Performance - Shares of Praxis Precision Medicines opened at $293.95, with a 52-week low of $26.70 and a high of $356.00 [4] - The company's 50-day moving average is $312.65, while the 200-day moving average is $206.81 [4] Earnings and Analyst Ratings - The company reported an EPS of ($3.50), missing the consensus estimate of ($3.00) by ($0.50) [4] - Analysts have a consensus rating of "Moderate Buy" with an average price target of $576.12, with three analysts rating it as Strong Buy and thirteen as Buy [5] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing precision therapies for neurological and psychiatric disorders [6] - The company targets specific ion channels and receptor subtypes to address unmet needs in conditions such as rare epilepsies and treatment-resistant depression [7]